The story of copyright's flagship drug presents a interesting case for stakeholders in the drug sector. While initially a tremendous success, producing vast sums, the exclusivity end and the subsequent entry of generic competitors have significantly affected income. This raises questions about the long-term viability of similar therapeutic developm